UK markets open in 5 hours 32 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
106.18-2.67 (-2.45%)
At close: 04:00PM EDT
106.14 -0.04 (-0.04%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close108.85
Open111.00
Bid106.13 x 500
Ask106.22 x 500
Day's range103.52 - 108.17
52-week range62.55 - 142.79
Volume2,744,382
Avg. volume3,777,022
Market cap41.676B
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    mRNA Platform Global Strategic Research Report 2024

    Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The report delves into the mRNA platform, examining its global competitive landscape and the market presence of key players. It provides a conceptual understanding of mRNA, highlighting its revolutionary approach to medicine and the significant scientific breakthroughs it represents. The introduction of mRNA vaccines is explored, emphasizing

  • ACCESSWIRE

    Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

    mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against ...

  • PR Newswire

    First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

    Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage